Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis -: Enough of a good thing

被引：30
作者：
Colon-Emeric, Cathleen S. [1 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2006年 / 296卷 / 24期
关键词：
D O I：
10.1001/jama.296.24.2968
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2968 / 2969
页数：2
相关论文
共 13 条
[1]   Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial [J].
Bauer, DC ;
Garnero, P ;
Hochberg, MC ;
Santora, A ;
Delmas, P ;
Ewing, SK ;
Black, DM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (02) :292-299
[2]   Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].
Black, Dennis M. ;
Schwartz, Ann V. ;
Ensrud, Kristine E. ;
Cauley, Jane A. ;
Levis, Silvina ;
Quandt, Sara A. ;
Satterfield, Suzanne ;
Wallace, Robert B. ;
Bauer, Douglas C. ;
Palermo, Lisa ;
Wehren, Lois E. ;
Lombardi, Antonio ;
Santora, Arthur C. ;
Cummings, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938
[3]   Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial [J].
Black, DM ;
Thompson, DE ;
Bauer, DC ;
Ensrud, K ;
Musliner, T ;
Hochberg, MC ;
Nevitt, MC ;
Suryawanshi, S ;
Cummings, SR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4118-4124
[4]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[5]   Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].
Bone, HG ;
Hosking, D ;
Devogelaer, J ;
Tucci, JR ;
Emkey, RD ;
Tonino, RP ;
Rodriguez-Portales, JA ;
Downs, RW ;
Gupta, J ;
Santora, AC ;
Liberman, UA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199
[6]   The effect of alendronate on fracture-related healthcare utilization and costs: The fracture intervention trial [J].
Chrischilles, EA ;
Dasbach, EJ ;
Rubenstein, LM ;
Cook, JR ;
Tabor, HK ;
Black, DM .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (08) :654-660
[7]   Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial [J].
Cummings, SR ;
Black, DM ;
Thompson, DE ;
Applegate, WB ;
Barrett-Connor, E ;
Musliner, TA ;
Palermo, L ;
Prineas, R ;
Rubin, SM ;
Scott, JC ;
Vogt, T ;
Wallace, R ;
Yates, AJ ;
LaCroix, AZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24) :2077-2082
[8]   Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT) [J].
Fink, HA ;
Ensrud, KE ;
Nelson, DB ;
Kerani, RP ;
Schreiner, PJ ;
Zhao, Y ;
Cummings, SR ;
Nevitt, MC .
OSTEOPOROSIS INTERNATIONAL, 2003, 14 (01) :69-76
[9]   Cost effectiveness of alendronate (Fosamax®) for the treatment of osteoporosis and prevention of fractures [J].
Johnell, O ;
Jönsson, B ;
Jönsson, L ;
Black, D .
PHARMACOECONOMICS, 2003, 21 (05) :305-314
[10]   Bisphosphonates: A review of their pharmacokinetic properties [J].
Lin, JH .
BONE, 1996, 18 (02) :75-85
12